Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Iconix Pharmaceuticals and Merck KGaA have entered into an agreement whereby several of the German firm's compounds will be compared with compounds from similar classes of molecules and with marketed products. This, it is hoped, will allow the companies to gain insight into the safety of new drug candidates in the early stages of preclinical development.
Subscribe to our email newsletter
In vitro toxicogenomics offers the potential for companies to reduce the attrition rate of compounds due to safety problems in the later stages of drug development, when those problems are far more costly. Iconix’ in vitro database includes gene expression profiles on 119 compound treatments on primary rat hepatocytes and is based on pathology, toxicology, and pharmacology endpoints from the company’s flagship in vivo database, DrugMatrix.
“By augmenting our in-house resources with Iconix’s expert toxicogenomics analysis and reporting services, we are able to jumpstart a program that promises to give us a better picture of a compound’s safety profile at an early stage of its development,” said Dr Phil Hewitt, from Merck KGaA.
“Companies like Merck KGaA are using this new in vitro approach to provide an early toxicology read on multiple compounds at lead optimization stage, and are seeing clear benefits by efficiently prioritizing the safer candidates for further development,” added Dr Donald Halbert, head of R&D for Iconix. “We expect that soon, the most competitive pharmaceutical companies will all be applying in vitro toxicogenomics to their decision making.”